Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172887 | 1.00 | ALDH1A1 (0.32) | ALDH1A1LMNACNR1CNR2 | |
| SCHEMBL2171477 | 1.00 | ALDH1A1 (0.32) | ALDH1A1LMNACNR1CNR2 | |
| SCHEMBL19263184 | 1.00 | ALDH1A1 (0.32) | ALDH1A1LMNACNR1CNR2 | |
| SCHEMBL16853951 | 0.89 | CNR2 (0.31) | ALDH1A1LMNACNR2 | |
| SCHEMBL2173087 | 0.89 | CNR2 (0.31) | ALDH1A1LMNACNR2 | |
| SCHEMBL7945603 | 0.89 | CNR2 (0.31) | ALDH1A1LMNACNR2 | |
| SCHEMBL3311795 | 0.89 | CNR2 (0.31) | ALDH1A1LMNACNR2 | |
| SCHEMBL19447840 | 0.86 | ALDH1A1 (0.32) | ALDH1A1LMNACNR2 | |
| SCHEMBL16869844 | 0.85 | CNR1 (0.32) | CNR1CNR2 | |
| SCHEMBL18721718 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-12-15 | — | — | US | disclosed |
| US-9296782-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20110224134-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-09-15 | — | — | US | disclosed |
| US-7973040-B2 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-02-04 | — | — | US | disclosed |
| WO-2010011566-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | ALDH1A1 125/4885LMNA 2421/4885CNR1 1793/4885 |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | ALDH1A1 112/4885LMNA 2502/4885CNR1 1459/4885 |
| US-20110224134-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | KEAP1, CTSC, SPINT2 | ALDH1A1 1419/4885LMNA 3876/4885CNR1 2658/4885 |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | KEAP1, CTSC, SPINT2 | ALDH1A1 1419/4885LMNA 3876/4885CNR1 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.